298 related articles for article (PubMed ID: 10769630)
21. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
22. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
23. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma.
Chu KU; Ravindranath MH; Gonzales A; Nishimoto K; Tam WY; Soh D; Bilchik A; Katopodis N; Morton DL
Cancer; 2000 Apr; 88(8):1828-36. PubMed ID: 10760759
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
25. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
26. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue.
Murray KP; Mathure S; Kaul R; Khan S; Carson LF; Twiggs LB; Martens MG; Kaul A
Gynecol Oncol; 2000 Feb; 76(2):176-82. PubMed ID: 10637067
[TBL] [Abstract][Full Text] [Related]
27. Role of lysosomal cathepsins in naphthazarin- and Fas-induced apoptosis in oral squamous cell carcinoma cells.
Johansson AC; Norberg-Spaak L; Roberg K
Acta Otolaryngol; 2006 Jan; 126(1):70-81. PubMed ID: 16308258
[TBL] [Abstract][Full Text] [Related]
28. The clinical significance of sialyl Lewis antigen expression in the spread of gastric cancer. Flow cytometric DNA analysis.
Ashizawa T; Aoki T; Yamazaki T; Katayanagi S; Shimizu H; Koyanagi Y
J Exp Clin Cancer Res; 2003 Mar; 22(1):91-8. PubMed ID: 12725328
[TBL] [Abstract][Full Text] [Related]
29. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
30. Expression of the carbohydrate tumour marker SLeX, SLeA (CA19-9), LeY and Thomsen-Friedenreich (TF) antigen on normal squamous epithelial tissue of the penis and vagina.
Wiest I; Schulze S; Kuhn C; Seliger C; Hausmann R; Betz P; Mayr D; Friese K; Jeschke U
Anticancer Res; 2007; 27(4A):1981-8. PubMed ID: 17649809
[TBL] [Abstract][Full Text] [Related]
31. Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis.
Guler N; Uckan S; Celik I; Oznurlu Y; Uckan D
Int J Oral Maxillofac Surg; 2005 Dec; 34(8):900-6. PubMed ID: 15907374
[TBL] [Abstract][Full Text] [Related]
32. Expression of complement regulatory proteins on human natural killer cell subsets.
Wang L; Halliday D; Johnson PM; Christmas SE
Immunol Lett; 2007 Oct; 112(2):104-9. PubMed ID: 17719652
[TBL] [Abstract][Full Text] [Related]
33. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death.
Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL
Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322
[TBL] [Abstract][Full Text] [Related]
34. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
35. [Immunohistochemical study of sialyl Lewis(a) antigen in oral squamous cell carcinoma: the association of sialyl Lewis(a) expression with local lymph metastasis].
Wu L; Chen Q; Huang W
Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Dec; 21(6):435-7. PubMed ID: 14732974
[TBL] [Abstract][Full Text] [Related]
36. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
37. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells.
Spiller OB; Morgan BP; Tufaro F; Devine DV
Eur J Immunol; 1996 Jul; 26(7):1532-8. PubMed ID: 8766557
[TBL] [Abstract][Full Text] [Related]
38. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
39. FasL gene therapy: a new therapeutic modality for head and neck cancer.
ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
[TBL] [Abstract][Full Text] [Related]
40. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
